MétaCan
Menu
← Back to cohort
Record W4415474614 · doi:10.1681/asn.20258naahvf7

Combination Treatment for Cardiorenal Protection in US Adults

2025· article· en· W4415474614 on OpenAlexaff
Massimo Nardone, Lisa Dubrofsky, Labib Imran Faruque, Mai Mohsen, Matthew Cooper, Modupe F. Olufemi, Tyler D. Brown, Ann Young, Bourne L. Auguste, Husam Abdel‐Qadir, Ron Wald, Frederik Persson, Christoph Wanner, Javed Butler, Peter Jüni, Nikolaus Marx, David Z.I. Cherney, Ayodele Odutayo

Bibliographic record

VenueJournal of the American Society of Nephrology · 2025
Typearticle
Languageen
FieldMedicine
TopicCardiac pacing and defibrillation studies
Canadian institutionsSunnybrook Health Science CentreWomen's College HospitalHealth Sciences CentreUniversity Health Network
Fundersnot available
KeywordsCardiorenal syndromeKidney diseaseMEDLINEHeart failureNephrology

Abstract

fetched live from OpenAlex

Background: Clinical guidelines recommend combined use of renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1RA) and nonsteroidal mineralocorticoid receptor antagonists (nsMRA). Few data exist on eligibility for combined treatment in US adults. Methods: Using the 2017-2020 National Health and Nutrition Examination Survey (NHANES), we estimated eligibility for combination treatment based on grade 1A to 2B recommendations for CKD or cardiovascular (CV) events in 6 clinical guidelines from KDIGO, AHA/ACC, ADA, and RCTs published after the guidelines (SELECT, FLOW, FINEARTS-HF). For combination treatment, we accounted for acute changes in eGFR, UACR and serum potassium at 3 months with each medication class before determining eligibility for the next medication class in the sequence. We stratified results by diabetes (DM) and CKD. We linked NHANES 2007-2016 to the 2018 Death Index to estimate all-cause and CV deaths in eligible adults. Using direct treatment effects of combination treatment from meta-analyses, we projected the number of prevented deaths. Results: Of 8152 adults, 15% had DM, 14% CKD and 5% DM and CKD (DKD). Mean age, eGFR, and UACR were 48yrs, 97ml/min/1.73m2, and 31mg/g. The dual-therapy with highest eligibility was RASi-SGLT2i, with 12% of the US population eligible (DM: 67%; CKD: 43%; DKD: 89%). The triple-therapy with highest eligibility was RASi-SGLT2i-GLP1RA, with 9% overall eligibility (DM: 58%; CKD: 26%; DKD: 67%). Eligibility for quadruple-therapy was 2% overall (DM: 15%; CKD:13%; DKD: 32%). Despite an overall 5% lower eligibility for triple therapy with RASi-SGLT2i-GLP1RA vs. dual therapy with RASi-SGLT2i, all-cause and CV deaths were reduced by ≥33% for RASi-SGLT2i-GLP1RA vs. RASi-SGLT2i, due to synergistic benefits. Conclusion: Eligibility for combined treatment with novel cardiorenal protective therapies is highly prevalent, particularly in DKD. Funding: Government Support – Non-U.S.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.005
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.006
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.004
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.310
Teacher spread0.290 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicCardiac pacing and defibrillation studies→French-language works237,207→